Companies Dominating the Gastroesophageal Reflux Disease (GERD) Landscape
- AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eisai Co., Ltd.
- GSK plc.
- Takeda Pharmaceutical Company Limited.
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- SFJ Pharmaceuticals
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals, Inc.
- Camber Pharmaceuticals, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- AstraZeneca PLC has successfully signed the global license agreement with KYM Biosciences Inc. for the development of CMG901, an antibody-drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers.
- Eisai Co., Ltd. and Bliss Biopharmaceutical Co., Ltd. have joined hands to develop BB-1701, an antibody-drug conjugate (ADC). This new drug is expected to have anti-tumor effects on breast, lung, and other solid tumors.
